{"title":"A Telementoring Program and Hepatitis C Virus Care in Rural Patients.","authors":"Ping Du, Xin Yin, Lan Kong, Jeah Jung","doi":"10.1089/tmr.2021.0001","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Rural patients with chronic hepatitis C virus (HCV) infection may be less likely to access HCV care than those in urban areas. A telementoring, task-shifting model has been implemented to address the unmet needs of HCV care. Evidence is needed on whether this intervention improves HCV care in rural HCV patients. <b>Methods:</b> We compared three key HCV care indicators among Medicare patients with chronic hepatitis C in 2014-2016 by urban-rural status between New Mexico with a telementoring program and Pennsylvania without such a program. We classified each patient's urban-rural status based on his or her ZIP code of residence. We used multivariable log-binomial regressions to examine the relative probability of receiving HCV care by urban and rural status in two states. <b>Results:</b> In New Mexico, 41.3% of HCV patients resided in rural areas (<i>N</i> = 1155). In Pennsylvania, rural patients accounted for 13.2% (<i>N</i> = 1775). The unadjusted overall rates of receiving HCV RNA or genotype testing within 12 months before HCV treatment were 76.1% in \"rural-New Mexico\" versus 73.3% in \"rural-Pennsylvania,\" 66.2% in \"urban-New Mexico,\" and 70.2% in \"urban-Pennsylvania.\" Post-treatment HCV RNA testing rate was also high in \"rural-New Mexico\" (83.0%). After adjusting for demographic and clinical characteristics, \"rural-New Mexico\" HCV patients who received HCV treatment still had the highest probability of taking HCV RNA or genotype testing before HCV treatment, compared with other groups (relative risk [95% confidence interval]: 0.91 [0.84-1.00] in \"rural-Pennsylvania,\" 0.85 [0.78-0.93] in \"urban-New Mexico,\" and 0.93 [0.87-1.00] in \"urban-Pennsylvania\"). <b>Conclusions:</b> The telementoring program may help improve HCV care in rural patients.</p>","PeriodicalId":22295,"journal":{"name":"Telemedicine reports","volume":" ","pages":"143-147"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142682/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Telemedicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/tmr.2021.0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Rural patients with chronic hepatitis C virus (HCV) infection may be less likely to access HCV care than those in urban areas. A telementoring, task-shifting model has been implemented to address the unmet needs of HCV care. Evidence is needed on whether this intervention improves HCV care in rural HCV patients. Methods: We compared three key HCV care indicators among Medicare patients with chronic hepatitis C in 2014-2016 by urban-rural status between New Mexico with a telementoring program and Pennsylvania without such a program. We classified each patient's urban-rural status based on his or her ZIP code of residence. We used multivariable log-binomial regressions to examine the relative probability of receiving HCV care by urban and rural status in two states. Results: In New Mexico, 41.3% of HCV patients resided in rural areas (N = 1155). In Pennsylvania, rural patients accounted for 13.2% (N = 1775). The unadjusted overall rates of receiving HCV RNA or genotype testing within 12 months before HCV treatment were 76.1% in "rural-New Mexico" versus 73.3% in "rural-Pennsylvania," 66.2% in "urban-New Mexico," and 70.2% in "urban-Pennsylvania." Post-treatment HCV RNA testing rate was also high in "rural-New Mexico" (83.0%). After adjusting for demographic and clinical characteristics, "rural-New Mexico" HCV patients who received HCV treatment still had the highest probability of taking HCV RNA or genotype testing before HCV treatment, compared with other groups (relative risk [95% confidence interval]: 0.91 [0.84-1.00] in "rural-Pennsylvania," 0.85 [0.78-0.93] in "urban-New Mexico," and 0.93 [0.87-1.00] in "urban-Pennsylvania"). Conclusions: The telementoring program may help improve HCV care in rural patients.